ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Clasificación en acciones
#19253
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Precio por acción
$0.3799409
Capitalización bursátil
$159.21M
Cambio (1 día)
-0.34%
Cambio (1 año)
-71.81%
País
CN
Comercio ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Categoría
Healthcare
Capitalización de mercado de ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Capitalización bursátil: $159.21M
A fecha de October 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. tiene una capitalización de mercado de $159.21M. Esto convierte a ImmuneOnco Biopharmaceuticals (Shanghai) Inc. en la 19253rd empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de ImmuneOnco Biopharmaceuticals (Shanghai) Inc. desde 2023 hasta 2026
1541 en comparación con los más populares 5 títulos stocks
